Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity

Acute myeloid leukemia (AML) can be treated with either high- or low-intensity regimens. Highly sensitive assays for measurable residual disease (MRD) now allow for a more precise assessment of response quality. We hypothesized that treatment (Rx) intensity may not be a key predictor of outcomes, as...

Descripción completa

Detalles Bibliográficos
Autores principales: Bazinet, Alexandre, Kadia, Tapan, Short, Nicholas J., Borthakur, Gautam, Wang, Sa A., Wang, Wei, Loghavi, Sanam, Jorgensen, Jeffrey, Patel, Keyur, DiNardo, Courtney, Daver, Naval, Alvarado, Yesid, Haddad, Fadi G., Pierce, Sherry, Nogueras Gonzalez, Graciela, Maiti, Abhishek, Sasaki, Koji, Yilmaz, Musa, Thompson, Philip, Wierda, William, Garcia-Manero, Guillermo, Andreeff, Michael, Jabbour, Elias, Konopleva, Marina, Huang, Xuelin, Kantarjian, Hagop, Ravandi, Farhad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Myeloid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10336257/
https://www.ncbi.nlm.nih.gov/pubmed/36884300
http://dx.doi.org/10.1182/bloodadvances.2022009391

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10336257/
https://www.ncbi.nlm.nih.gov/pubmed/36884300
http://dx.doi.org/10.1182/bloodadvances.2022009391

Ejemplares similares